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To examine the efﬁcacy and safety of tadalaﬁl in the treatment of lower urinary tract symptoms
suggestive of benign prostatic hyperplasia with chronic pelvic pain syndrome, we treated 23 Japanese men
with tadalaﬁl 5 mg once daily for 4 weeks. The mean age of the participants was 58.7 years and the prostate
volume was 25. 2 ml. Signiﬁcant improvements in total International Prostatic Symptom Score,
International Prostatic Symptom Score Quality of Life Index, total National Institutes of Health Chronic
Prostatitis Symptom Index score, pain subscore, urinary symptom subscore, and quality of life impact
subscore, were observed for tadalaﬁl versus before treatment. These ﬁndings conﬁrm that tadalaﬁl is a
valuable new treatment option for patients with benign prostatic hyperplasia complicated by chronic pelvic
pain syndrome.
(Hinyokika Kiyo 63 : 101-105, 2017 DOI : 10.14989/ActaUrolJap_63_3_101)
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Table 1. Baseline patient characteristics
Number 23
Age (range) 58.7 (52-64)
PSA (range) 1.35 ng/ml (0.160-2.980)
Prostate volume (range) 25.2 ml (19.6-32.6)






Daily alcohol intake 16
Long hours of sitting 14
Daily exercise 18
泌62,08,0◆-1

























（52∼64歳），PSA 値は 1.35 ng/ml（0.160∼2.980 ng/








Tadalaﬁl 4 週間の投与により，IPSS トータルスコ
アは 17.3±5.4 から 11.9±4.9 へと投与前に比べて
有意に改善した（p＜0.01 ; Fig. 1）．QOL スコアも
5.1±1.4 から 2.9±1.5 へと有意に改善した（p＜
0.01 ; Fig. 1）．
NIH-CPSI については，トータルスコアが 30.9±
12.8 から 19.5±11.2 へと有意に改善した（p＜
0.01 ; Fig. 2a）．サブスコアについても，痛みや不快
感に関するスコア（問 1 ∼ 4）が 13.5±3.8 から
7.4±3.1 へ（Fig. 2b），排尿に関するスコアである残
尿感（問 5）が 3.8±1.2 から 2.6±1.2 へ，頻尿
（問 6）が 4.0±1.9 から 2.9±1.1 へ（Fig. 2c），症状
の影響や QOL に関するスコア（問 7∼ 9）が 9.6±
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Fig. 2. Change in NIH-CPSI of subjects treated with tadalaﬁl 5 mg daily for 4 weeks. a) NIH-CPSI total score. b)
NIH-CPSI pain domain score. c) NIH-CPSI urinary domain score. d) NIH-CPSI QOL domain score.
候群であり，1995年に NIH（National Institutes of
Health）から提唱された分類1)に基づいて策定された






















































Tadalaﬁl は選択的かつ強力な PDE5 阻害作用を有す
る薬剤であり，血管，膀胱，尿道，前立腺，陰茎海綿
体などの下部尿路の平滑筋において，強力な平滑筋弛

































してタムスロシン 0.4 mg，レボフロキサシン 500 mg，
インドメタシン坐剤 100 mg をグループA，それにタ
ダラフィル 5 mg を追加した群をグループ Bとし，投


















1) Litwin MS, McNaughton-Collins M, Fowler FJ Jr, et
al. : he National Institutes of Health chronic prostatitis
symptom index : development and validation of a new
outcome measure. Chronic Prostatitis Collaborative
Research Network. J Urol 162 : 369-375, 1999
2) Nickel JC, Nyberg LM, Hennenfent M, et al. :
Research guidelines for chronic prostatitis : consensus
report from the ﬁrst National Institutes of Health
International Prostatitis Collaborative Network. Urol-
ogy 54 : 229-233, 1999
3) Nickel JC, Downey J, Johnston B, et al. : Predictors of
patient response to antibiotic therapy for the chronic
prostatitis/chronic pelvic pain syndrome : a prospec-
tive multicenter clinical trial. J Urol 165 : 1539-1544,
2001
4) Cheah PY, Liong ML, Yuen KH, et al. : Terazosin
therapy for chronic prostatitis/chronic pelvic pain
syndrome : a randomized, placebo controlled trial. J
泌尿紀要 63巻 3号 2017年104
Urol 169 : 592-596, 2003
5) Roehrborn CG, Kaplan SA, Noble WD, et al. : The
impact of acute or chronic inﬂammation in baseline
biopsy on the risk of clinical progression of BPH :
results from the MTOPS study. J Urol 173 : 346,
2005
6) Robert G, Descazeaud A, Nicolaïew N, et al. : Inﬂam-
mation in benign prostatic hyperplasia : a 282 pa-
tients’immunohistochemical analysis. Prostate 69 :
1774-1780, 2009
7) Collins MM, Meigs JB, Barry MJ, et al. : Prevalence
and correlates of prostatitis in the health professionals
follow-up study cohort. J Urol 167 : 1363-1366,
2002
8) Nickel JC, Elhilali M, Vallancien G, et al. : Benign
prostatic hyperplasia (BPH) and prostatitis : prevalence
of painful ejaculation in men with clinical BPH. BJU
Int 95 : 571-574, 2005
9) Morelli A, Sarchielli E, Comeglio P, et al. : Phosphodi-
esterase type 5 expression in human and rat lower
urinary tract tissues and the effect of tadalaﬁl on
prostate gland oxygenation in spontaneously hyper-
tensive rats. J Sex Med 8 : 2746-2760, 2011
10) Uckert S, Sormes M, Kedia G, et al. : Effects of
phosphodiesterase inhibitors on tension induced by
norepinephrine and accumulation of cyclic nucleotides
in isolated human prostatic tissue. Urology 71 : 526-
530, 2008
11) Yoshinaga R, Kawai Y, Oka M, et al. : Effect of a
single treatment with tadalaﬁl on blood ﬂow in lower
urinary tract tissues in rat models of bladder overdis-
tension/emptying and abdominal aorta clamping/
release. Eur J Pharmacol 754 : 92-97, 2015
12) Kawai Y, Oka M, Yoshinaga R, et al. : Effects of the
phosphodiesterase 5 inhibitor Tadalaﬁl on bladder
function in a rat model of partial bladder outlet
obstruction. Neurourol Urodyn 35 : 444-449, 2016
13) Minagawa T, Aizawa N, Igawa Y, et al. : Inhibitory
effects of phosphodiesterase 5 inhibitor, tadalaﬁl, on
mechanosensitive bladder afferent nerve activities of
the rat, and on acrolein-induced hyperactivity of these
nerves. BJU Int 110 : E259-E266, 2012
14) Morelli A, Comeglio P, Filippi S, et al. : Mechanism of
action of phosphodiesterase type 5 inhibition in
metabolic syndrome-associated prostate alterations : an
experimental study in the rabbit. Prostate 73 : 428-
441, 2013
15) Otari KV and Upasani CD : Involvement of NO-
cGMP pathway in anti-hyperalgesic effect of PDE5
inhibitor tadalaﬁl in experimental hyperalgesia. In-
ﬂammopharmacology 23 : 187-194, 2015
16) Kirby RS, Carson C and Dasgupta P : Daily phos-
phodiesterase type 5 inhibitor therapy : a new treat-
ment option for prostatitis/prostatodynia ? BJU Int
113 : 694-695, 2014
17) Hasan HF : The use of tadalaﬁlin patients with chronic
prostatitis/chronic pelvic pain syndrome. Iragi J
Med Sci 11 : 78-83, 2013
(Accepted on November 4, 2016)
Received on August 3, 2016
西野，ほか : 慢性骨盤痛症候群・Tadalaﬁl 105
